VTRS
Viatris
$15.75
▲ 2.4%Updated Today 5:06 AM ET
▲ Up 75.3% over the last 12 months
Market Cap
$18.68B
P/E
—
Forward P/E (est.)
—
ROE
-2.0%
Revenue Growth
1.6%
EPS Growth
—
Profit Margin
-2.0%
FCF Yield
24.7%
Debt / Equity
0.98x
ROIC
-19.0%
Interest Coverage
—
Current Ratio
1.6x
Dividend Yield
3.1%
Implied Growth (rev. DCF)
-1.2%
Rating Score
29/100
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what VTRS's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. VTRS trades near $15.75, above its 50-day average ($15.72) and 200-day average ($13.01). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 51 it is in neutral territory — neither stretched nor washed out.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently negative — short-term momentum is fading.
Volatility — ATR. Average True Range is the typical daily move. VTRS's is $0.49 (~3.1% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month VTRS found buyers near $14.94 (support) and sellers near $16.76 (resistance); its 52-week range is $8.63–$17.53. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.9× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
Viatris (VTRS) is a large-cap company in the Pharmaceuticals industry, part of the Health Care sector of the S&P 500, with a market value around $18.68B.
In its latest reported year it generated about $14.25B in revenue.
Our model rates VTRS Weak (29/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
4Y CAGR
-5.4%
Revenue moved from $17.81B in 2021 to $14.25B in 2025, a -5.4% compound annual growth rate. The most recent year was roughly flat (1.6%) year over year. Slower, mature growth is common for established businesses.
Gross Margin
35.2%
Operating Margin
-18.7%
Net Margin
-2.0%
ROE
-2.0%
Viatris keeps about -2.0% of each sales dollar as net profit, with a 35.2% gross margin and -18.7% operating margin. Return on equity is -2.0% and return on invested capital about -19.0%. The company is currently unprofitable on a net basis.
Total Debt
$11.54B
Net Debt
$9.73B
Net Debt / EBITDA
—
Debt / Equity
0.98x
Leverage: debt-to-equity is 1.0x, with a current ratio of 1.6x. That is a moderate, manageable debt load for most businesses. It carries roughly $11.54B of total debt against $1.80B of cash.
Operating CF
$2.32B
Free Cash Flow
$1.94B
FCF Margin
13.6%
In the latest year Viatris produced about $2.32B of operating cash flow and $1.94B of free cash flow after capital spending. That is a free-cash-flow yield of about 24.7% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
P/E
—
P/S
1.34x
P/B
0.96x
EV / EBITDA
—
VTRS trades at n/a trailing earnings, 1.3x sales, and 1.0x book value. Reverse-engineering today's price implies the market expects roughly -1.2% long-term free-cash-flow growth. With no positive trailing earnings, value it on sales, cash flow, or growth rather than P/E.
Where this stock sits versus what most companies trade at.
Typical ranges are general references (e.g., many stocks trade at ~18–26x earnings), not hard rules. Context only — not investment advice.
How VTRS stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (59 S&P 500 companies), VTRS ranks #57 of 59 by our overall rating.
P/E vs sector
—
median 25.5x
ROE vs sector
-2.0%
median 14.9%
Growth vs sector
1.6%
median 7.9%
Sector rank
#57
of 59 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 59 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$5.11 – $8.51
vs. $15.75 today · expected CAGR -20% – -12%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $14.68B | $15.12B | $15.57B | $16.04B | $16.52B |
| Net income | $440.34M | $453.55M | $467.15M | $481.17M | $495.60M |
| EPS | $0.38 | $0.39 | $0.40 | $0.41 | $0.43 |
| Share price (low) | $4.54 | $4.67 | $4.81 | $4.96 | $5.11 |
| Share price (high) | $7.56 | $7.79 | $8.02 | $8.26 | $8.51 |
| CAGR (low–high) | -71% / -52% | -46% / -30% | -33% / -20% | -25% / -15% | -20% / -12% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for VTRS:
- Healthy free-cash-flow yield (~24.7%) funds buybacks and dividends.
- Pays a 3.1% dividend on top of any price gains.
The case against VTRS:
- Revenue growth is slow (1.6%), limiting the upside engine.
- Thin net margins (-2.0%) leave little room for error.
- Our model's overall read is Weak (29/100).
Growth risk — sluggish revenue (1.6%) leaves little margin for execution missteps.
Margin risk — thin profitability (-2.0%) is vulnerable to cost or pricing pressure.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Viatris is a large-cap health care business growing at a mature pace, with modest profitability, and a heavier debt load to watch. It trades at n/a earnings, which our model scores Weak (29/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
VTRS — frequently asked questions
Is VTRS a good stock to buy?
We don't give buy or sell advice. Our model rates Viatris Weak (29/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is VTRS's rating on The Stocks School?
Viatris currently scores 29/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does VTRS's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Viatris's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for VTRS calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this VTRS analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell VTRS. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.